{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:22:36Z","timestamp":1790490156199,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1111\/bjh.17448","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T07:58:45Z","timestamp":1623398325000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pembrolizumab combined with carfilzomib and low\u2010dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE\u2010023 study"],"prefix":"10.1111","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[{"name":"Department of Hematology University Hospital Hotel\u2010Dieu Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razi","family":"Ghori","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Marinello","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Merck & Co., Inc. Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Department of Clinical and Translational Medicine Clinical Universidad de Navarra CIMA IDISNA, CIBERONC Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0184"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.79"},{"key":"e_1_2_7_4_1","volume-title":"KEYTRUDA\u00ae (pembrolizumab) for injection, for intravenous use","year":"2020"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01389"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15888"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7"},{"key":"e_1_2_7_11_1","unstructured":"FDA places clinical hold on three studies evaluating pembrolizumab in multiple myeloma [press release]. The ASCO Post; July 7 2017.http:\/\/www.ascopost.com\/News\/57813. Accessed January 4 2021."},{"key":"e_1_2_7_12_1","volume-title":"KYPROLIS\u00ae (carfilzomib) for injection, for intravenous use","year":"2020"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1803602"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17448","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T05:56:59Z","timestamp":1692856619000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/bjh.17448"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17448","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"2021-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}